RU2008123556A - Составы, имеющие цитокин модулирующие свойства - Google Patents
Составы, имеющие цитокин модулирующие свойства Download PDFInfo
- Publication number
- RU2008123556A RU2008123556A RU2008123556/15A RU2008123556A RU2008123556A RU 2008123556 A RU2008123556 A RU 2008123556A RU 2008123556/15 A RU2008123556/15 A RU 2008123556/15A RU 2008123556 A RU2008123556 A RU 2008123556A RU 2008123556 A RU2008123556 A RU 2008123556A
- Authority
- RU
- Russia
- Prior art keywords
- cytokine
- interleukin
- phosphate
- phosphate derivatives
- hydroxychromanes
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title claims abstract 33
- 108090000695 Cytokines Proteins 0.000 title claims abstract 33
- 239000000203 mixture Substances 0.000 title claims 6
- 238000000034 method Methods 0.000 claims abstract 39
- FVOOPOSZDXPIMS-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-2-ol Chemical class C1=CC=C2OC(O)CCC2=C1 FVOOPOSZDXPIMS-UHFFFAOYSA-N 0.000 claims abstract 14
- 102000015696 Interleukins Human genes 0.000 claims abstract 8
- 108010063738 Interleukins Proteins 0.000 claims abstract 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract 8
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims abstract 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims abstract 6
- 230000004957 immunoregulator effect Effects 0.000 claims abstract 6
- 102000003390 tumor necrosis factor Human genes 0.000 claims abstract 6
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract 4
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract 4
- 102000003815 Interleukin-11 Human genes 0.000 claims abstract 4
- 108090000177 Interleukin-11 Proteins 0.000 claims abstract 4
- 102000003816 Interleukin-13 Human genes 0.000 claims abstract 4
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract 4
- 102000003810 Interleukin-18 Human genes 0.000 claims abstract 4
- 108090000171 Interleukin-18 Proteins 0.000 claims abstract 4
- 102000004388 Interleukin-4 Human genes 0.000 claims abstract 4
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract 4
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract 4
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract 4
- 102000004890 Interleukin-8 Human genes 0.000 claims abstract 4
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract 4
- 102000009618 Transforming Growth Factors Human genes 0.000 claims abstract 4
- 108010009583 Transforming Growth Factors Proteins 0.000 claims abstract 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract 4
- 210000003714 granulocyte Anatomy 0.000 claims abstract 4
- 239000003102 growth factor Substances 0.000 claims abstract 4
- 230000002757 inflammatory effect Effects 0.000 claims abstract 4
- 229940076144 interleukin-10 Drugs 0.000 claims abstract 4
- 229940074383 interleukin-11 Drugs 0.000 claims abstract 4
- 229940028885 interleukin-4 Drugs 0.000 claims abstract 4
- 229940100601 interleukin-6 Drugs 0.000 claims abstract 4
- 229940079322 interferon Drugs 0.000 claims abstract 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims abstract 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims abstract 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims abstract 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims abstract 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims abstract 2
- 102000004125 Interleukin-1alpha Human genes 0.000 claims abstract 2
- 108010082786 Interleukin-1alpha Proteins 0.000 claims abstract 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract 2
- 229940096397 interleukin-8 Drugs 0.000 claims abstract 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims abstract 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 34
- 229910019142 PO4 Inorganic materials 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000008139 complexing agent Substances 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 4
- 239000010452 phosphate Substances 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
- 230000007234 antiinflammatory process Effects 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004355 nitrogen functional group Chemical group 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 102400000739 Corticotropin Human genes 0.000 claims 2
- 101800000414 Corticotropin Proteins 0.000 claims 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- 102000009151 Luteinizing Hormone Human genes 0.000 claims 2
- 108010073521 Luteinizing Hormone Proteins 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims 2
- 102100038803 Somatotropin Human genes 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229960000258 corticotropin Drugs 0.000 claims 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 2
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229940040129 luteinizing hormone Drugs 0.000 claims 2
- 239000000199 parathyroid hormone Substances 0.000 claims 2
- 229960001319 parathyroid hormone Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical class OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 claims 1
- XYYUAOIALFMRGY-UHFFFAOYSA-N 3-[2-carboxyethyl(dodecyl)amino]propanoic acid Chemical compound CCCCCCCCCCCCN(CCC(O)=O)CCC(O)=O XYYUAOIALFMRGY-UHFFFAOYSA-N 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- 102400000321 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 102000003946 Prolactin Human genes 0.000 claims 1
- 108010057464 Prolactin Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000002280 amphoteric surfactant Substances 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000005018 casein Substances 0.000 claims 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims 1
- 235000021240 caseins Nutrition 0.000 claims 1
- 239000003093 cationic surfactant Substances 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940097325 prolactin Drugs 0.000 claims 1
- 239000011731 tocotrienol Substances 0.000 claims 1
- 229930003802 tocotrienol Natural products 0.000 claims 1
- 235000019148 tocotrienols Nutrition 0.000 claims 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005907306 | 2005-12-23 | ||
| AU2005907306A AU2005907306A0 (en) | 2005-12-23 | Formulations having cytokine regulating properties | |
| AU2006901179 | 2006-03-08 | ||
| AU2006901179A AU2006901179A0 (en) | 2006-03-08 | Formulations having cytokine regulating properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008123556A true RU2008123556A (ru) | 2010-01-27 |
Family
ID=38188188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008123556/15A RU2008123556A (ru) | 2005-12-23 | 2006-12-22 | Составы, имеющие цитокин модулирующие свойства |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090005348A1 (enExample) |
| EP (1) | EP1973547A1 (enExample) |
| JP (1) | JP2009520697A (enExample) |
| KR (1) | KR20080085839A (enExample) |
| BR (1) | BRPI0621081A2 (enExample) |
| CA (1) | CA2631653A1 (enExample) |
| IL (1) | IL191880A0 (enExample) |
| RU (1) | RU2008123556A (enExample) |
| WO (1) | WO2007070981A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040097472A1 (en) * | 2000-11-14 | 2004-05-20 | West Simon Michael | Complexes of phosphate derivatives |
| AUPR549901A0 (en) | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
| MXPA04000654A (es) | 2001-07-27 | 2004-03-19 | Vital Health Sciences Pty Ltd | Terapia dermica usando derivados de fosfato de agente de transferencia de electrones. |
| AUPR684801A0 (en) * | 2001-08-06 | 2001-08-30 | Vital Health Sciences Pty Ltd | Supplement therapy |
| AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| JP4690305B2 (ja) * | 2003-01-17 | 2011-06-01 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | 抗増殖性質を有する化合物 |
| AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
| RU2477136C2 (ru) * | 2004-03-03 | 2013-03-10 | Вайтал Хэлф Сайнсис Пти Лтд | Алкалоидные составы |
| WO2006012692A1 (en) * | 2004-08-03 | 2006-02-09 | Vital Health Sciences Pty Ltd | Carrier for enteral administration |
| RU2428973C2 (ru) * | 2005-03-03 | 2011-09-20 | Вайтал Хэлф Сайнсис Пти Лтд | Составы, обладающие липидопонижающими свойствами |
| US20090239827A1 (en) * | 2005-03-03 | 2009-09-24 | Esra Ogru | Compounds having lipid lowering properties |
| US9168216B2 (en) | 2005-06-17 | 2015-10-27 | Vital Health Sciences Pty. Ltd. | Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| WO2011094814A1 (en) | 2010-02-05 | 2011-08-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| CA2794734C (en) | 2010-03-30 | 2017-12-12 | Phosphagenics Limited | Transdermal delivery patch |
| WO2012122586A1 (en) * | 2011-03-15 | 2012-09-20 | Phosphagenics Limited | New composition |
| MX365403B (es) | 2012-01-09 | 2019-05-31 | Serpin Pharma Llc | Peptidos y metodos para usarlos. |
| US20150251407A1 (en) * | 2014-03-05 | 2015-09-10 | Heath Moore | Painting mask with specialized indicia |
| AU2016317726B2 (en) * | 2015-08-28 | 2022-05-26 | Serpin Pharma, Llc | Methods for treatment of diseases |
| US10973761B2 (en) | 2015-12-09 | 2021-04-13 | Phosphagenics Limited | Pharmaceutical formulation |
| US20200060311A1 (en) | 2016-12-09 | 2020-02-27 | Avecho Biotechnology Limited | A method for improving performance parameters of an animal |
| JP7198754B2 (ja) | 2016-12-21 | 2023-01-04 | アベーチョ バイオテクノロジー リミテッド | 方法 |
| JP6870847B2 (ja) * | 2017-04-12 | 2021-05-12 | 日本メナード化粧品株式会社 | Ｉｌ−８及びｇｍ−ｃｓｆ発現抑制剤 |
| WO2022082256A1 (en) | 2020-10-19 | 2022-04-28 | Avecho Biotechnology Limited | Oral cannabinoid formulation comprising tocopheryl phosphates and long chain triglycerides or long chain fatty acids |
| WO2022082257A1 (en) | 2020-10-19 | 2022-04-28 | Avecho Biotechnology Limited | Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates |
| CA3201637A1 (en) | 2020-11-18 | 2022-05-27 | Novartis Ag | Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy |
| WO2022155656A1 (en) | 2021-01-13 | 2022-07-21 | Rodan & Fields, Llc | Cosmetic compositions |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2407823A (en) * | 1946-09-17 | Antihemorrhagic esters and methods | ||
| US2667479A (en) * | 1951-01-30 | 1954-01-26 | Merck & Co Inc | Benzimidazole phosphate |
| US2913477A (en) * | 1957-03-22 | 1959-11-17 | Merck & Co Inc | Antihemorrhagic compounds and processes for preparing the same |
| US3127434A (en) * | 1959-10-20 | 1964-03-31 | Hoffmann La Roche | Dihydrovitamin k monophosphate compounds and preparation thereof |
| US3212901A (en) * | 1961-06-07 | 1965-10-19 | Eastman Kodak Co | Stabilized tocopherol concentrates and process for preparing the same |
| DE2526938C2 (de) * | 1975-02-14 | 1982-04-22 | F. Hoffmann-La Roche & Co. AG, 4002 Basel | Vitaminpräparate |
| US4141938A (en) * | 1976-10-07 | 1979-02-27 | Hoechst Aktiengesellschaft | Production of acid orthophosphoric acid ester mixtures |
| US4444755A (en) * | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
| US4299906A (en) * | 1979-06-01 | 1981-11-10 | American Hoechst Corporation | Light-sensitive color proofing film with surfactant in a light-sensitive coating |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| IT1157269B (it) * | 1982-03-19 | 1987-02-11 | Seuref Ag | Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica |
| CH661438A5 (it) * | 1984-04-09 | 1987-07-31 | Seuref Ag | Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale. |
| JPS6191137A (ja) * | 1984-10-11 | 1986-05-09 | Kao Corp | 外用薬剤組成物 |
| DE3702766A1 (de) * | 1987-01-30 | 1988-08-11 | Henkel Kgaa | Verfahren zur herstellung und isolierung von monoalkylphosphorsaeureestern |
| JP3070744B2 (ja) * | 1987-04-10 | 2000-07-31 | 株式会社日立製作所 | ベクトル処理装置 |
| US4952495A (en) * | 1987-06-08 | 1990-08-28 | Eastman Kodak Company | Hydrolyzable compounds which release electron transfer agents and analytical use of same |
| US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US5053222A (en) * | 1989-06-07 | 1991-10-01 | Shiseido Company Ltd. | Hair cosmetic composition |
| US5094848A (en) * | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
| DE3927113C2 (de) * | 1989-08-17 | 1993-11-25 | Dolorgiet Gmbh & Co Kg | Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung |
| IT1236843B (it) * | 1989-11-22 | 1993-04-21 | Simes | Processo per la preparazione di 4-0-fosfati di dopamina o suoi derivati |
| US5374645A (en) * | 1990-01-22 | 1994-12-20 | Ciba-Geigy Corporation | Transdermal administation of ionic pharmaceutically active agents via aqueous isopropanol |
| FR2657526B1 (fr) * | 1990-01-31 | 1994-10-28 | Lvmh Rech | Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues. |
| US5041434A (en) * | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| US5114957A (en) * | 1990-05-08 | 1992-05-19 | Biodor U.S. Holding | Tocopherol-based antiviral agents and method of using same |
| SE9003665D0 (sv) * | 1990-11-16 | 1990-11-16 | Kabivitrum Ab | Morphine prodrugs |
| FR2679904A1 (fr) * | 1991-08-01 | 1993-02-05 | Lvmh Rech | Utilisation d'un phosphate de tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, ou pharmaceutiques et compositions ainsi obtenues. |
| US5643597A (en) * | 1991-08-01 | 1997-07-01 | Lvmh Recherche | Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained |
| US5474891A (en) * | 1991-10-30 | 1995-12-12 | Thomas Jefferson University | Plasma-based platelet concentrate preparations with additive |
| EP0543417A1 (en) * | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotrienols and tocotrienol-like compounds and methods for their use |
| US5282312A (en) * | 1991-12-31 | 1994-02-01 | Tessera, Inc. | Multi-layer circuit construction methods with customization features |
| US5741518A (en) * | 1992-08-03 | 1998-04-21 | L'oreal | Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids |
| US5773457A (en) * | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
| WO1994008599A1 (en) * | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
| US6384043B1 (en) * | 1993-02-01 | 2002-05-07 | Gholam A. Peyman | Methods of alleviating pain sensations of the denuded eye with opioid analgesics |
| TW252918B (enExample) * | 1993-03-31 | 1995-08-01 | Senju Pharma Co | |
| US5807542A (en) * | 1993-11-27 | 1998-09-15 | Knoll Aktiengesellschaft | Chemical compositions for inhibiting nitrosation reaction in toiletries and cosmetics |
| FR2715565B1 (fr) * | 1994-01-31 | 1996-03-15 | Oreal | Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation. |
| US5554781A (en) * | 1994-03-30 | 1996-09-10 | Reierson; Robert L. | Monoalkyl phosphonic acid ester production process |
| TW287103B (enExample) * | 1994-04-22 | 1996-10-01 | Senju Pharma Co | |
| US5589504A (en) * | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
| CA2152693A1 (en) * | 1994-08-05 | 1996-02-06 | Kazumi Ogata | Therapeutic composition for pancreatitis |
| HU215966B (hu) * | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum |
| FR2730928B1 (fr) * | 1995-02-23 | 1997-04-04 | Oreal | Composition a base de vesicules lipidiques a ph acide et son utilisation en application topique |
| US5607968A (en) * | 1995-06-07 | 1997-03-04 | Avon Products, Inc. | Topical alkyl-2-O-L-ascorbyl-phosphates |
| CN1069320C (zh) * | 1995-10-17 | 2001-08-08 | 昭和电工株式会社 | 高纯度生育酚磷酸酯,其生产方法和含有该化合物的化妆品 |
| FR2741263B1 (fr) * | 1995-11-22 | 1997-12-26 | Oreal | Composition comprenant une dispersion aqueuse de vesicules lipidiques encapsulant un filtre uv a fonction acide et utilisations en application topique |
| US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| US5885595A (en) * | 1996-05-13 | 1999-03-23 | Elizabeth Arden Co., Division Of Conopco, Inc. | Cosmetic composition with a retinol fatty acid ester |
| CA2209690A1 (en) * | 1996-07-31 | 1998-01-31 | Sachiko Matsuura | Therapeutic drug for acne vulgaris |
| US6022867A (en) * | 1996-11-27 | 2000-02-08 | Showa Denko Kabushiki Kaisha | Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals |
| US5804168A (en) * | 1997-01-29 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for protecting and treating sun damaged skin |
| CA2282513C (en) * | 1997-03-13 | 2007-09-18 | Hexal Ag | Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations |
| US7179486B1 (en) * | 1997-04-01 | 2007-02-20 | Nostrum Pharmaceuticals, Inc. | Process for preparing sustained release tablets |
| DE19824983C2 (de) * | 1997-06-04 | 2001-06-28 | Pacific Corp | 2-(3-Aminopropylphosphorsäure)-L-ascorbat, Verfahren zu seiner Herstellung und dieses enthaltende kosmetische Zubereitung zur Aufhellung der Haut |
| US5928631A (en) * | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
| US5906811A (en) * | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
| US5776915A (en) * | 1997-08-12 | 1998-07-07 | Clarion Pharmaceuticals Inc. | Phosphocholines of retinoids |
| US6096326A (en) * | 1997-08-15 | 2000-08-01 | Scandinavian-American Import/Export Corporation | Skin care compositions and use |
| US6461623B2 (en) * | 1998-04-13 | 2002-10-08 | Kao Corporation | Cosmetic composition |
| US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
| JP2002519366A (ja) * | 1998-07-07 | 2002-07-02 | トランスダーマル・テクノロジーズ・インコーポレーテツド | 医薬的に活性な作用物質を迅速かつ非刺激的に経皮送達するための組成物、およびそのような組成物の調剤法およびそれらの送達 |
| US6770672B1 (en) * | 1998-09-23 | 2004-08-03 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| US6703384B2 (en) * | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| IL142082A (en) * | 1998-09-23 | 2005-12-18 | Res Dev | Tocoflowers, tocotrinols, derivatives as a novel and other side-chain and their uses |
| WO2000027402A1 (fr) * | 1998-11-06 | 2000-05-18 | Senju Pharmaceutical Co., Ltd. | Remedes destines a une administration topique pour lutter contre des maladies allergiques du type iv |
| US6048891A (en) * | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
| AUPQ037499A0 (en) * | 1999-05-14 | 1999-06-10 | Swig Pty Ltd | Improved process for phosphorylation and compounds produced by this method |
| AUPP829399A0 (en) * | 1999-01-25 | 1999-02-18 | Swig Pty Ltd | Recovery for chroman derivatives |
| US6184247B1 (en) * | 1999-05-21 | 2001-02-06 | Amway Corporation | Method of increasing cell renewal rate |
| US6423742B1 (en) * | 1999-09-02 | 2002-07-23 | Drake Larson | Compositions for reducing vascular plaque formation and methods of using same |
| CA2385989A1 (en) * | 1999-09-27 | 2001-04-05 | Andrew Nienstedt | Compositions of tocol-soluble therapeutics |
| RU2263672C2 (ru) * | 2000-02-11 | 2005-11-10 | Рисерч Дивелопмент Фаундейшн | Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение |
| US6635253B2 (en) * | 2000-02-29 | 2003-10-21 | Showa Denko Kabushiki Kaisha | Composition for enhancing immunological effects |
| AU2001236001A1 (en) * | 2000-02-29 | 2001-09-12 | Showa Denko K.K. | Immune enhancement compositions and use thereof |
| US6346544B2 (en) * | 2000-03-02 | 2002-02-12 | Oklahoma Medical Research Foundation | Desmethyl tocopherols for protecting cardiovascular tissue |
| US6444220B2 (en) * | 2000-03-16 | 2002-09-03 | Teresa S. Wiley | Method and compositions for changing the contour of skin |
| US6361800B1 (en) * | 2000-04-13 | 2002-03-26 | Cooper Concepts, Inc. | Multi-vitamin and mineral supplement |
| US6485950B1 (en) * | 2000-07-14 | 2002-11-26 | Council Of Scientific And Industrial Research | Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions |
| JP4818500B2 (ja) * | 2000-09-05 | 2011-11-16 | 株式会社ペンタプラストア | トコトリエノール誘導体及びその製造方法 |
| US20030206972A1 (en) * | 2000-10-13 | 2003-11-06 | Babish John G. | Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect |
| AUPR549901A0 (en) * | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
| US20040097472A1 (en) * | 2000-11-14 | 2004-05-20 | West Simon Michael | Complexes of phosphate derivatives |
| US20020151467A1 (en) * | 2000-12-21 | 2002-10-17 | Leung Frank K. | Methods and compositions for oral insulin delivery |
| US20020131994A1 (en) * | 2001-01-10 | 2002-09-19 | Schur Henry B. | Non-irritating formulation for the transdermal delivery of substances |
| US6849271B2 (en) * | 2001-04-27 | 2005-02-01 | Verion, Inc. | Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods |
| MXPA04000654A (es) * | 2001-07-27 | 2004-03-19 | Vital Health Sciences Pty Ltd | Terapia dermica usando derivados de fosfato de agente de transferencia de electrones. |
| AUPR684801A0 (en) * | 2001-08-06 | 2001-08-30 | Vital Health Sciences Pty Ltd | Supplement therapy |
| WO2003024429A1 (en) * | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
| AU2002951045A0 (en) * | 2002-08-27 | 2002-09-12 | Vital Health Sciences Pty Ltd | Method of supplementing nascent endogenous storage forms |
| US20030144219A1 (en) * | 2001-11-15 | 2003-07-31 | Phinney Stephen Dodge | Formulations and methods for treatment or amelioration of inflammatory conditions |
| WO2003049774A1 (en) * | 2001-12-13 | 2003-06-19 | Vital Health Sciences Pty Ltd | Transdermal transport of compounds |
| AU2002950713A0 (en) * | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| US20040067890A1 (en) * | 2002-10-04 | 2004-04-08 | Gupta Shyam K. | Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions |
| JP4690305B2 (ja) * | 2003-01-17 | 2011-06-01 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | 抗増殖性質を有する化合物 |
| US7033998B2 (en) * | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
| AU2003901812A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphates of secondary alcohols |
| AU2003901813A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Pharmaceutical derivatives |
| RU2477136C2 (ru) * | 2004-03-03 | 2013-03-10 | Вайтал Хэлф Сайнсис Пти Лтд | Алкалоидные составы |
-
2006
- 2006-12-22 US US12/158,932 patent/US20090005348A1/en not_active Abandoned
- 2006-12-22 CA CA002631653A patent/CA2631653A1/en not_active Abandoned
- 2006-12-22 BR BRPI0621081-3A patent/BRPI0621081A2/pt not_active IP Right Cessation
- 2006-12-22 WO PCT/AU2006/001997 patent/WO2007070981A1/en not_active Ceased
- 2006-12-22 RU RU2008123556/15A patent/RU2008123556A/ru not_active Application Discontinuation
- 2006-12-22 EP EP06828077A patent/EP1973547A1/en not_active Withdrawn
- 2006-12-22 KR KR1020087014490A patent/KR20080085839A/ko not_active Withdrawn
- 2006-12-22 JP JP2008546038A patent/JP2009520697A/ja active Pending
-
2008
- 2008-06-02 IL IL191880A patent/IL191880A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2631653A1 (en) | 2007-06-28 |
| BRPI0621081A2 (pt) | 2011-11-29 |
| US20090005348A1 (en) | 2009-01-01 |
| EP1973547A1 (en) | 2008-10-01 |
| KR20080085839A (ko) | 2008-09-24 |
| JP2009520697A (ja) | 2009-05-28 |
| WO2007070981A1 (en) | 2007-06-28 |
| IL191880A0 (en) | 2008-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009520697A5 (enExample) | ||
| Liles et al. | Nomenclature and biologic significance of cytokines involved in inflammation and the host immune response | |
| McGee et al. | Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines | |
| Aman et al. | Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist | |
| Bellomo | The cytokine network in the critically ill | |
| US6660258B1 (en) | Oromucosal cytokine compositions and uses thereof | |
| Odeh | The role of tumour necrosis factor‐α in acquired immunodeficiency syndrome | |
| JP2022524754A (ja) | 癌を処置するためにｉＲＧＤと共投与される低用量サイトカイン | |
| Gately | Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors | |
| WO2007070981A1 (en) | Compounds having cytokine modulating properties | |
| EP0311138B1 (en) | Compounds for the induction of in vivo and vitro production of cytokines | |
| AU762360B2 (en) | Oromucosal cytokine compositions and uses thereof | |
| Fibbe et al. | The role of interleukin-1 in hematopoiesis | |
| Feldmann et al. | T cells and lymphokines | |
| RU2008100307A (ru) | Применение цитокина из семейства интерлейкина-6 для получения композиции для комбинированного введения с интерфероном-альфа | |
| Ohya et al. | Ability of orally administered IFN-α-containing transgenic potato extracts to inhibit Listeria monocytogenes infection | |
| Maury | Anaemia in rheumatoid arthritis: role of cytokines | |
| Tilg et al. | Suppression of interleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression? | |
| JP4414494B2 (ja) | 白血球減少症の予防剤および治療剤 | |
| UA106591C2 (uk) | Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1 | |
| JPH05505799A (ja) | 感染性抗原チャレンジに対する免疫応答促進のためのｉｌ―４の使用 | |
| Wilson et al. | The effect of folic acid (Lactobacillus casei factor) in nutritional hematopenia of monkeys | |
| Rodenas et al. | Cyclic neutropenia: a cause of recurrent aphthous stomatitis not to be missed | |
| CN1535724A (zh) | 重组人干扰素用于预防严重性急性呼吸道综合征的新用途 | |
| RU97112047A (ru) | Способ лечения внутримозговой опухоли головного мозга |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110801 |